2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2110

Synovial Fibroblasts Regulate B Cell Survival Via B Cell Activating Factor of the TNF Family (BAFF)
Abstract Number: 587

Synovial Immunophenotype and Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiological Prognosis
Abstract Number: 153

Synovial Immunophenotype and Ultrasonography: A Contemporaneous Study of Different Compartments of the Knee Joint
Abstract Number: 3218

Synovial Mast Cells Associate with High Disease Activity and Predict Radiographic Progression at 12 Months in Patients with Early Rheumatoid Arthritis
Abstract Number: 1030

Synovial Tissue Resident Macrophages Play the Protective Role in the Development of Inflammatory Arthritis in CD11c-Flip-KO Mice
Abstract Number: 134

Synovitis Assessed By the German 7-Joint Ultrasound Score (US7S) Is Associated with the Reversible Activity-Related Component of Physical Disability in Patients with Rheumatoid Arthritis
Abstract Number: 157

Synovitis of Sternoclavicular and Peripheral Joints Can be Detected By Ultrasound in Patients with SAPHO Syndrome
Abstract Number: 1403

Systematic Appraisal of the American College of Rheumatology Clinical Practice Guidelines
Abstract Number: 1161

Systematic Development of a Patient-Centered Strategy to Improve Tight Control in Daily Clinical Practice
Abstract Number: 1404

Systematic Review and Appraisal of Quality Measures for Inflammatory Arthritis
Abstract Number: 2945

Systematic Review: “Efficacy and Safety of Biological Versus Immunosuppressive Therapy Compared to Placebo in the Treatment of Uveitis Associated with BehçEt’s Disease.”
Abstract Number: 121

Systemic Lupus Erythematosus (SLE) Is a Salient Cause of Premature Mortality in the United States: A Sex-Based Exploration
Abstract Number: 792

Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] Response Is Associated with Global Benefit in Patients with Moderate to Severe SLE
Abstract Number: 1762

Systemic Lupus Erythematosus and the Evaluation of Poor Sleep
Abstract Number: 1760

Systemic Lupus Erythematosus in Immigrants: Results from the 1000 Canadian Faces of Lupus Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].